Caiyu Lin

1.4k total citations
43 papers, 1.1k citations indexed

About

Caiyu Lin is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Caiyu Lin has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 22 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Caiyu Lin's work include Lung Cancer Treatments and Mutations (20 papers), PI3K/AKT/mTOR signaling in cancer (12 papers) and Cancer Mechanisms and Therapy (6 papers). Caiyu Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), PI3K/AKT/mTOR signaling in cancer (12 papers) and Cancer Mechanisms and Therapy (6 papers). Caiyu Lin collaborates with scholars based in China and United States. Caiyu Lin's co-authors include Xiujie Wang, Huijie Guo, Liuqi Yang, Yong He, Yubo Wang, Li Li, Rui Han, Conghua Lu, Hengyi Chen and Li Wang and has published in prestigious journals such as Clinical Cancer Research, Developmental Cell and Journal of Ethnopharmacology.

In The Last Decade

Caiyu Lin

41 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caiyu Lin China 17 680 443 262 261 97 43 1.1k
Jun Cao China 23 810 1.2× 562 1.3× 418 1.6× 336 1.3× 91 0.9× 74 1.6k
Shibu Thomas United States 21 634 0.9× 412 0.9× 348 1.3× 521 2.0× 59 0.6× 71 1.5k
Yidan Ren China 14 622 0.9× 252 0.6× 307 1.2× 121 0.5× 109 1.1× 23 1.0k
Dekuang Zhao United States 15 723 1.1× 531 1.2× 317 1.2× 113 0.4× 88 0.9× 29 1.2k
Mi Ran Yun South Korea 22 622 0.9× 558 1.3× 268 1.0× 483 1.9× 93 1.0× 49 1.4k
Wanyeon Kim South Korea 24 977 1.4× 341 0.8× 602 2.3× 228 0.9× 86 0.9× 45 1.6k
Junjeong Choi South Korea 17 746 1.1× 441 1.0× 645 2.5× 136 0.5× 115 1.2× 42 1.4k
Kui Sheng Chen China 2 606 0.9× 216 0.5× 241 0.9× 144 0.6× 65 0.7× 5 1.0k
Lei Bi China 17 543 0.8× 218 0.5× 215 0.8× 123 0.5× 94 1.0× 46 977

Countries citing papers authored by Caiyu Lin

Since Specialization
Citations

This map shows the geographic impact of Caiyu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caiyu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caiyu Lin more than expected).

Fields of papers citing papers by Caiyu Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caiyu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caiyu Lin. The network helps show where Caiyu Lin may publish in the future.

Co-authorship network of co-authors of Caiyu Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Caiyu Lin. A scholar is included among the top collaborators of Caiyu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caiyu Lin. Caiyu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Jie, Han She, Rui Han, et al.. (2025). Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis. Developmental Cell. 60(23). 3267–3284.e7. 1 indexed citations
2.
Liu, Yihui, Rui Han, Jie Zheng, et al.. (2025). Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC. Advanced Healthcare Materials. 14(9). e2404087–e2404087. 2 indexed citations
3.
Wang, Zhiguo, Yan Dong, Li Li, et al.. (2024). AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells. The Tohoku Journal of Experimental Medicine. 262(4). 269–276.
4.
Zhou, Tianjun, et al.. (2024). Multisnapshot High-Resolution Gridless DOA Estimation for Uniform Circular Arrays. IEEE Signal Processing Letters. 31. 1705–1709. 3 indexed citations
5.
Zheng, Jie, Jun Kang, Liping Wang, et al.. (2024). Mesoporous manganese nanocarrier target delivery metformin for the co-activation STING pathway to overcome immunotherapy resistance. iScience. 27(7). 110150–110150. 6 indexed citations
6.
Lu, Conghua, Chen Hu, Yihui Liu, et al.. (2024). Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. Journal for ImmunoTherapy of Cancer. 12(6). e009165–e009165. 9 indexed citations
7.
He, Zhengyao, et al.. (2023). Research on low-frequency bender disk transducer driven by multiple relaxor ferroelectric single crystal disks. Applied Acoustics. 216. 109808–109808. 1 indexed citations
8.
Wang, Yubo, Rui Han, Chen Hu, et al.. (2023). Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance. Japanese Journal of Clinical Oncology. 54(1). 89–96. 1 indexed citations
9.
Li, Li, Zhujun Li, Conghua Lu, et al.. (2022). Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling. Communications Biology. 5(1). 155–155. 26 indexed citations
10.
Lu, Conghua, Rui Yu, Chong Zhang, et al.. (2022). Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC. Cell Death Discovery. 8(1). 221–221. 9 indexed citations
11.
Wang, Yubo, Chen Hu, Mengxiao Zhu, et al.. (2022). Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer. Thoracic Cancer. 13(22). 3162–3173. 9 indexed citations
12.
Chen, Hengyi, Conghua Lu, Caiyu Lin, et al.. (2021). VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy. Carcinogenesis. 42(6). 880–890. 9 indexed citations
13.
Wang, Yubo, Rui Han, Qiushi Wang, et al.. (2021). Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients. International Journal of General Medicine. Volume 14. 347–356. 8 indexed citations
14.
Lin, Caiyu, Hengyi Chen, Rui Han, et al.. (2021). Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer. Thoracic Cancer. 12(23). 3184–3193. 16 indexed citations
15.
Chen, Hengyi, Caiyu Lin, Tao Peng, et al.. (2020). Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell Death and Disease. 11(2). 111–111. 20 indexed citations
16.
Wang, Yubo, Caiyu Lin, Rui Han, et al.. (2020). Metformin attenuates TGF-β1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-β pathways. 3 Biotech. 10(6). 287–287. 12 indexed citations
17.
Han, Rui, Shuai Hao, Conghua Lu, et al.. (2020). Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction. Molecular Oncology. 14(6). 1152–1169. 26 indexed citations
18.
Lin, Caiyu, Conghua Lu, Li Li, et al.. (2018). Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling. The Clinical Respiratory Journal. 12(12). 2642–2652. 11 indexed citations
19.
Li, Li, Rui Han, Hualiang Xiao, et al.. (2014). Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal. Clinical Cancer Research. 20(10). 2714–2726. 204 indexed citations
20.
Lin, Caiyu, Li Wang, Hong Wang, et al.. (2013). Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL‐6/STAT3/NF‐kB signaling pathways. Journal of Cellular Biochemistry. 114(9). 2061–2070. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Cao Breakdown of academic impact, for papers by Shibu Thomas Breakdown of academic impact, for papers by Yidan Ren Breakdown of academic impact, for papers by Dekuang Zhao Breakdown of academic impact, for papers by Mi Ran Yun Breakdown of academic impact, for papers by Wanyeon Kim Breakdown of academic impact, for papers by Junjeong Choi Breakdown of academic impact, for papers by Kui Sheng Chen Breakdown of academic impact, for papers by Lei Bi
Rankless by CCL
2026